Israel Englander Gain Therapeutics, Inc. Transaction History

Millennium Management LLC

  • $175 Billion
  • Q1 2025

Shares

4 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 14, 2024
SELL
$1.24 - $3.99 $26,093 - $83,961
-21,043 Reduced 47.38%
23,373 $29,000
Q1 2024

May 15, 2024
BUY
$3.21 - $5.04 $101,602 - $159,526
31,652 Added 247.98%
44,416 $167,000
Q4 2023

Feb 14, 2024
BUY
$2.07 - $3.4 $418 - $686
202 Added 1.61%
12,764 $41,000
Q2 2023

Aug 14, 2023
BUY
$4.36 - $5.5 $54,770 - $69,091
12,562 New
12,562 $56,000

About Gain Therapeutics, Inc.

GANX Quotes by TradingView
  • Ticker GANX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 11,883,400
  • Market Cap $21.4M
  • Description
  • Gain Therapeutics, Inc., a biotechnology company, engages in developing various therapies to treat diseases caused by protein misfolding. It focuses on rare genetic diseases and neurological disorders. The company uses its Site-Directed Enzyme Enhancement Therapy platform to discover allosteric sites on misfolded proteins and identify proprietar...
More about GANX
Track Israel Englander's Portfolio

Track Israel Englander Portfolio

Follow Israel Englander (Millennium Management LLC) and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Millennium Management LLC, based on Form 13F filings with the SEC.

News

Stay updated on Millennium Management LLC and Israel Englander with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email